Janus Henderson Group PLC Boosts Stake in Hims & Hers Health, Inc. (NYSE:HIMS)

Janus Henderson Group PLC raised its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 17.3% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 80,069 shares of the company's stock after acquiring an additional 11,800 shares during the period. Janus Henderson Group PLC's holdings in Hims & Hers Health were worth $1,936,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in HIMS. Barclays PLC raised its stake in Hims & Hers Health by 9.7% during the 3rd quarter. Barclays PLC now owns 308,363 shares of the company's stock valued at $5,680,000 after acquiring an additional 27,231 shares during the last quarter. Nisa Investment Advisors LLC raised its stake in Hims & Hers Health by 115.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 4,560 shares of the company's stock valued at $110,000 after acquiring an additional 2,442 shares during the last quarter. SG Americas Securities LLC raised its stake in Hims & Hers Health by 44.0% during the 4th quarter. SG Americas Securities LLC now owns 104,422 shares of the company's stock valued at $2,525,000 after acquiring an additional 31,915 shares during the last quarter. Raleigh Capital Management Inc. raised its stake in Hims & Hers Health by 1,100.0% during the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after acquiring an additional 1,100 shares during the last quarter. Finally, KBC Group NV raised its stake in Hims & Hers Health by 107.9% during the 4th quarter. KBC Group NV now owns 8,471 shares of the company's stock valued at $205,000 after acquiring an additional 4,396 shares during the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Stock Performance

Hims & Hers Health stock opened at $57.91 on Thursday. The stock has a fifty day moving average of $37.10 and a two-hundred day moving average of $34.54. The company has a market capitalization of $12.96 billion, a price-to-earnings ratio of 131.61 and a beta of 1.84. Hims & Hers Health, Inc. has a fifty-two week low of $13.47 and a fifty-two week high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.08. The company had revenue of $586.01 million during the quarter, compared to the consensus estimate of $535.21 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. Hims & Hers Health's revenue was up 110.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.05 earnings per share. On average, analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have commented on HIMS. Morgan Stanley reduced their price objective on Hims & Hers Health from $60.00 to $40.00 and set an "equal weight" rating for the company in a research note on Tuesday, April 29th. Truist Financial cut their target price on Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating for the company in a research note on Thursday, April 10th. Piper Sandler reissued a "neutral" rating and set a $39.00 target price (up from $35.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. UBS Group reissued a "mixed" rating on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Finally, TD Cowen downgraded Hims & Hers Health from a "buy" rating to a "hold" rating and cut their target price for the stock from $44.00 to $30.00 in a research note on Tuesday, April 29th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $37.67.

Insider Transactions at Hims & Hers Health

In other news, insider Irene Becklund sold 2,203 shares of the firm's stock in a transaction on Thursday, April 3rd. The stock was sold at an average price of $28.78, for a total transaction of $63,402.34. Following the sale, the insider now owns 8,007 shares in the company, valued at $230,441.46. This trade represents a 21.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Andrew Dudum sold 128,127 shares of the firm's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $33.98, for a total value of $4,353,755.46. Following the sale, the chief executive officer now owns 173,655 shares in the company, valued at $5,900,796.90. This trade represents a 42.46% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 618,936 shares of company stock worth $25,182,692 over the last quarter. 13.71% of the stock is currently owned by insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.